AAV-MP-84-EGFP

AAV-MP-84-EGFP series viruses are ready to use AAV vectors carrying MP-84-EGFP expression cassette, in which the EGFP reporter is droved by a MP-84 promoter. The AAV-MP-84-EGFP vectors are available with 16 different serotypes, and there are over 1000 AAV serotypes/variants to be choose for custom AAV packaging.
The MP-84 promoter is a micro-promoter derived from the promoter of human insulin gene. Despite its compact size (84 base pairs), it demonstrates robust activity that is comparable to, or only slightly weaker than, the much larger CAG promoter across a wide range of cell types and tissues both in vitro and in vivo. Strong expression has been documented in human islet endocrine cells, hepatocytes, brain, and muscle tissues, among others. By conserving AAV packaging capacity, micro-promoters like MP-84 enable the delivery of larger therapeutic genes that cannot be accommodated with conventional large universal promoters.
By employing EGFP as a reporter, researchers gain the ability to effortlessly visualize and quantify the transduction efficiency of AAV vectors within target cells, further enhancing the precision of their experiments.

Please contact us at for specific academic pricing.

Background

AAV viruses or AAV vectors, are a convenient solution for researchers who need to perform gene delivery experiments, such as gene therapy, gene editing, and gene regulation. The premade AAV viruses are available in various serotypes, promoters, and reporters/transgenes, allowing researchers to choose the most suitable vector for their specific research application. With over a thousand known AAV serotypes, customers have the tools to rapidly determine the vector specificity for various cell types. Additionally, the availability of multiple promoters paired with reporter genes allows for easy assessment and monitoring of gene expression levels and timing.

To ensure high-quality and pure products, various assays are used to assess the quality and purity of their AAV vectors:
· Gene specific qPCR Titer: Target the specific transgenes or common used elements, such as WPRE, CMV, PolyA, but not ITR.
· Full/Empty Particle Ratio: Ensure all the premade AAVs has >80% full particles by Mass Photometry.
· Endotoxin Testing: Ensure safety with endotoxin level <1U/1e13VG.
· SDS-PAGE Gel: Assess the purity of the AAV viruses is great than 95%.
· Infectivity Assay: Evaluate the efficiency of AAV viruses in transducing target cells if they have reporters.